Rituximab (RTX) is an anti-CD20 antibody used successfully in Granulomatosis with Polyangiitis (GPA) for induction and maintenance of remission. Our study aims to evaluate the long term efficacy and safety of chronic pre-emptive RTX therapy in GPA.
Retrospective study of 35 GPA patients treated with RTX between April 2004 and September 2011 for active disease and maintenance. RTX was initiated as two 1-gram infusions 2 weeks apart and thereafter 2gr RTX was re-administered annually. Patients were followed for 47 (2-88) months. They received a median RTX dose of 8g (2-13) dealt in 5 (1-10) rounds.
Risk factors for severe infections determined by univariate and multivariate (backward stepwise) binary logisitic regression analysis. All predictor variables in the analysis are continuous.
Risk factors for chronic infections determined by univariate and multivariate (backward stepwise) binary logistic regression. All predictors variables in this analysis are continuous.
Severe infections (necessitating hospitalization and IV antibiotics)
Severe infections (necessitating hospitalization and IV antibiotics) Chronic infections (symptomatic localized infections lasting >3 months and requiring several antibiotics courses)
Chronic infections (symptomatic localized infections lasting >3 months and requiring several antibiotics courses)
Lower B cells at RTX initiation in patients with chronic infections compared with patients without chronic infections (Mann-Whitney U test: 0.035 vs. 0.09x10^9/L, p=0.065) 30.9 relapses /100 patient-years before RTX
